REDWOOD CITY, Calif., Sept. 18 /PRNewswire-FirstCall/ -- Maxygen, Inc. , a biotechnology company focused on the development of improved protein drugs, today announced that it will present at the 2007 UBS Global Life Sciences Conference on Tuesday, September 25, 2007 at 12:00 p.m. Eastern Time. Russell Howard, Maxygen’s chief executive officer, will present.
A live webcast of the presentation can be accessed on Maxygen’s website at http://www.maxygen.com/webcasts. A replay of the presentation will be available starting at approximately 3:00 p.m. Eastern Time on September 25, and will be available until October 27, 2007.
About Maxygen
Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. We look for opportunities where our proprietary protein modification technologies can address significant therapeutic needs. Products developed by Maxygen now in clinical trials include a novel interferon-alpha for the treatment of hepatitis C virus (HCV) infection and a novel G-CSF for the treatment of neutropenia. Maxygen’s approach may allow us to leverage the established development and regulatory paths of approved drugs. We believe this advantage translates to a greater chance of successfully bringing important new drugs to market. http://www.maxygen.com
Maxygen, Inc.
CONTACT: Michele Boudreau of Maxygen, Inc., +1-650-279-2088,michele.boudreau@maxygen.com
